4.5 Letter

A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

期刊

BONE MARROW TRANSPLANTATION
卷 57, 期 2, 页码 295-298

出版社

SPRINGERNATURE
DOI: 10.1038/s41409-021-01527-z

关键词

-

资金

  1. Public Health Service from the National Cancer Institute (NCI) [U24CA076518]
  2. Public Health Service from the National Heart, Lung and Blood Institute (NHLBI) [U24CA076518]
  3. Public Health Service from the National Institute of Allergy and Infectious Diseases (NIAID) [U24CA076518]
  4. Health Resources and Services Administration (HRSA) [HHSH250201700006C]
  5. Office of Naval Research [N00014-20-1-2705, N00014-20-1-2832]
  6. Be the Match Foundation
  7. Medical College of Wisconsin
  8. National Marrow Donor Program
  9. AbbVie
  10. Actinium Pharmaceuticals, Inc.
  11. Adaptive Biotechnologies Corporation
  12. Adienne SA
  13. Allovir, Inc.
  14. Amgen, Inc.
  15. Angiocrine Bioscience
  16. Astellas Pharma US
  17. Bluebird Bio, Inc.
  18. Bristol Myers Squibb Co.
  19. CSL Behring
  20. CytoSen Therapeutics, Inc.
  21. Daiichi Sankyo Co., Ltd.
  22. Eurofins Viracor
  23. ExcellThera
  24. Fate Therapeutics
  25. Gamida-Cell, Ltd.
  26. Genentech Inc
  27. GlaxoSmithKline
  28. Incyte Corporation
  29. Janssen/Johnson Johnson
  30. Jasper Therapeutics
  31. Jazz Pharmaceuticals, Inc.
  32. Karyopharm Therapeutics
  33. Kiadis Pharma
  34. Kite, a Gilead Company
  35. Kyowa Kirin
  36. Legend Biotech
  37. Magenta Therapeutics
  38. Medac GmbH
  39. Merck Co.
  40. Millennium, the Takeda Oncology Co.
  41. Miltenyi Biotec, Inc.
  42. MorphoSys
  43. Novartis Pharmaceuticals Corporation
  44. Omeros Corporation
  45. Oncoimmune, Inc.
  46. Orca Biosystems, Inc.
  47. Pfizer, Inc.
  48. Pharmacyclics, LLC
  49. Sanofi Genzyme
  50. Seagen, Inc.
  51. Stemcyte
  52. Takeda Pharmaceuticals
  53. Tscan
  54. Vertex
  55. Vor Biopharma
  56. Xenikos BV
  57. [K23 HL141445]

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据